Compare NHC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHC | ARQT |
|---|---|---|
| Founded | 1971 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 1997 | 2020 |
| Metric | NHC | ARQT |
|---|---|---|
| Price | $225.87 | $27.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 111.1K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | 17.46 | ★ 88.79 |
| EPS | ★ 2.27 | N/A |
| Revenue | ★ $1,517,781,000.00 | $376,072,000.00 |
| Revenue This Year | N/A | $34.85 |
| Revenue Next Year | N/A | $29.39 |
| P/E Ratio | $97.58 | ★ N/A |
| Revenue Growth | 16.09 | ★ 91.34 |
| 52 Week Low | $94.04 | $13.70 |
| 52 Week High | $232.25 | $31.77 |
| Indicator | NHC | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 64.23 | 53.86 |
| Support Level | $154.31 | $24.96 |
| Resistance Level | N/A | $27.79 |
| Average True Range (ATR) | 7.73 | 1.25 |
| MACD | 0.06 | -0.19 |
| Stochastic Oscillator | 77.25 | 32.90 |
National Healthcare Corp provides long-term care facilities. Its principal business includes operating skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs. The company's activities include providing sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative care, memory and Alzheimer's care, senior living services, and home health care services. In addition, the company also provides management services, accounting, and financial services, as well as insurance services to third-party operators of healthcare facilities. Its reportable segments include Inpatient services and Home care and hospice services. The majority of revenue is derived from the Inpatient services segment.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.